Archive
This is a library of Lhasa's blog articles.
Filter by Category
Filter by Author
- Alex Cayley
- Alex Harding
- Ally Reeves
- Alun Myden
- Anax Oliveira
- Andrew Thresher
- Ash Ali
- Cheuk Man Tsang
- Chris Barber
- Crina Heghes
- Daragh Connolly
- Dave Yeo
- David Ponting
- Emma Scrafton
- Fabrizio Campo
- Fernanda Waechter
- Grace Kocks
- Hazel Gardiner
- James McManus
- Jess Tidmarsh
- Jessica Magallanes-Castaneda
- Josh Cosby
- Kelly Gallagher
- Laura Johnston
- Liz Covey-Crump
- Martyn Chilton
- Michael Burns
- Nik Marchetti
- Oana Leonte
- Paul Imeson
- Pearl Saville
- Rachael Tennant
- Rachel Hemingway
- Raeesah Saddiq
- Rob Foster
- Sara Atkinson
- Scott McDonald
- Susanne Stalford
Filter by Product
Supporting N-nitrosamine risk assessments for drug products
N-Nitrosamine risk assessment and control have become an integral part of pharmaceutical drug product development. In this article, we discuss 3 key stages of risk assessment: identifying the source of risk, determining the level of activity and mitigating the risk. Discover how our in silico tools can be used to support informed decision making on chemical safety, in this blog article.
25 July 2022
20 tips for nitrosamine impurity assessment
Many readers will be aware of the risk posed by nitrosamine impurities, as an ongoing pharmaceutical industry hot topic. In July 2021 ANVISA published their guidance for assessment and control of potentially carcinogenic nitrosamines in active pharmaceutical ingredients and drug products. To discuss this topic, we invited knowledgeable speakers from ANVISA, Industry - GSK and Libbs Farmacêutica - and Lhasa to give their perspectives on this topic. This article details the top 20 take away points from the workshop for quick and easy consumption - enjoy!
05 August 2021
Predicting forced degradation pathways: Learning how to get the most out of Zeneth
Are you getting the most out of Zeneth, Lhasa’s expert, knowledge-based in silico software for the prediction of forced degradation pathways of organic active pharmaceutical ingredients (APIs)?
19 April 2021
Zeneth and ICH Q3B
The ICH Q3B (Impurities in New Drug Products) guideline provides guidance on the qualification of impurities in new drug substances produced by chemical syntheses. This article discusses how Zeneth, Lhasa Limited’s expert decision support software for predicting the forced degradation of organic compounds, can help to satisfy ICH Q3B.
15 October 2020